The endometrial cancer data from the ATAC (arimidex, tamoxifen, alone or in combination) trial indicates a protective effect of anastrozole (arimidex) upon the endometrium

被引：0
作者：
Duffy, SR
Greenwood, M
机构：
[1] AstraZeneca, Alderley Pk, England
[2] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
134
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
[41]   The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment [J].
Duffy, S ;
Jackson, TL ;
Lansdown, M ;
Philips, K ;
Wells, M ;
Pollard, S ;
Clack, G ;
Coibion, M ;
Bianco, AR .
HUMAN REPRODUCTION, 2006, 21 (02) :545-553
[42]   Data from the arimidex, tamoxifen, alone or in combination (ATAQ trial: Implications for use of aromatase inhibitors in 2003 [J].
Buzdar, AU .
CLINICAL CANCER RESEARCH, 2004, 10 (01) :355S-361S
[43]   Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status [J].
Dowsett, M .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 :S7-S7
[44]   Aromatase inhibitors in prevention - Data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second international breast cancer intervention study) [J].
Cuzick, J .
TUMOR PREVENTION AND GENETICS, 2003, 163 :96-103
[45]   Impact of adjuvant chemotherapy prior to endocrine therapy: 68 month results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. [J].
Buzdar, AU .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :30S-30S
[46]   Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) - Data reported on behalf of the ATAC('arimidex', tamoxifen, alone or in combination) trialists' group [J].
Houghton, Joan .
ANNALS OF ONCOLOGY, 2006, 17 :94-94
[47]   Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer [J].
David Cella ;
Lesley Fallowfield ;
Peter Barker ;
Jack Cuzick ;
Gershon Locker ;
Anthony Howell .
Breast Cancer Research and Treatment, 2006, 100 :273-284
[48]   Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen alone or in combination) trial [J].
R Mansel ;
G Locker ;
L Fallowfield ;
Á Benedict ;
D Jones .
British Journal of Cancer, 2007, 97 :152-161
[49]   Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial [J].
Mansel, R. ;
Locker, G. ;
Fallowfield, L. ;
Benedict, A. ;
Jones, D. .
BRITISH JOURNAL OF CANCER, 2007, 97 (02) :152-161
[50]   Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer [J].
Cella, David ;
Fallowfield, Lesley ;
Barker, Peter ;
Cuzick, Jack ;
Locker, Gershon ;
Howell, Anthony .
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) :273-284
12345